|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis:results from a long-term comparative study显示文摘 | Ringe D Dorst A Faber H | 2003 | Osteoporos Int2003，14，： | 1 |
| 2 | Differential A* 显示文摘 | Trovato K I Dorst L | 2002 | IEEE Transactions on Knowledge and Data Engineering2002，14，6： | 1 |
| 3 | The limited difference between keratin patterns of squamous cell carcinomas and adenocarcinomas is explicable by both cell lineage and state of differentiation of tumour cells 显示文摘 | van Dorst EB van Muijen GN Litvinov SV | 1998 | J Clin Pathol1998，51，9： | 1 |
| 4 | The National hurricane research project:50 years of research,rough rides,and name changes显示文摘 | Dorst N M | | 0，，： | 1 |
| 5 | Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis:results from a long-term comparative study显示文摘 | Ringe JD Dorst A Faber H | 2003 | Osteoporos Int2003，14，10： | 1 |
| 6 | John Gero's function behaviour structure model of designing:a critical analysis显示文摘 | Dorst K Vermaas P E | 2005 | Research in Engineering Design2005，16，12： | 1 |
| 7 | Functional transcranial Doppler sonography and a spatial orientation paradigm identify the non-domi- nant hemisphere显示文摘 | Dorst J Haag A Knake S et ai | 2008 | Brain Cogn2008，68，： | 1 |
| 8 | Activity and expression of JNK1,P38 and ERK kinase,c-jun N-terminal phosphorylation, and c-jun promoter binding in the adult rat brain following kainate-induced seizures显示文摘 | Mielke K Brecht S Dorst A | 1999 | Neuroscience1999，91，2： | 1 |
| 9 | Creativity in the design process: co-evolution of problem-solution 显示文摘 | DORST K CROSS N | 2001 | Design Studies2001，22，5： | 1 |
| 10 | On the conceptual frame- work of John Gem's FBS model and the prescriptive aims of design methodology 显示文摘 | Pieter E Vermaas Kees Dorst | 2007 | Design Studies2007，28，： | 1 |
| 11 | Activation and expression of JNK1, p38 and ERK kinase, c-Jun N-terminal phosphorylation and c-jun promoter binding in the adult rat brain following kainatainduced seizures 显示文摘 | Mielke K Brecht S Dorst A | 1999 | Neuroscience1999，91，2： | 1 |
| 12 | Creativity in the design process : co-evolution of problem solution显示文摘 | DORST K CROSS N | 2001 | Design Studies2001，22，5： | 1 |
| 13 | Differential A*显示文摘 | Leo Dorst | 2002 | IEEE Transactions on Knowledge and Data Engineering2002，14，6： | 1 |
| 14 | In vitro selection and characterization of DNA aptamers recognizing chloram- phenicol显示文摘 | Mehta J Van Dorst B Rouah - Martin E | 2011 | Journal of Biotechnology2011，155，4： | 1 |
| 15 | Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study 显示文摘 | RINGE JD DORST A FABER H | 2003 | Osteoporos Int2003，14，10： | 1 |
| 16 | Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, twoarm study显示文摘 | Ringe J Dorst A Faber H | 2004 | Rheumatol Int2004，24，11： | 1 |
| 17 | Creativity in the design process: co-evolu- tion of problem solution 显示文摘 | Dorst K Crnss N | 2001 | Design Studies2001，22，5： | 1 |
| 18 | Neuroflament light and heterogeneity of disease progression in amyotrophic lateral sclerosis:development and validation of a prediction model to improve interventional trials显示文摘Background:Interventional trials in amyotrophic lateral sclerosis(ALS)sufer from the heterogeneity of the disease as it considerably reduces statistical power.We asked if blood neuroflament light chains(NfL)could be used to antici‑pate disease progression and increase trial power.Methods:In 125 patients with ALS from three independent prospective studies-one observational study and two interventional trials-we developed and externally validated a multivariate linear model for predicting disease pro‑gression,measured by the monthly decrease of the ALS Functional Rating Scale Revised(ALSFRS-R)score.We trained the prediction model in the observational study and tested the predictive value of the following parameters assessed at diagnosis:NfL levels,sex,age,site of onset,body mass index,disease duration,ALSFRS-R score,and monthly ALSFRS-R score decrease since disease onset.We then applied the resulting model in the other two study cohorts to assess the actual utility for interventional trials.We analyzed the impact on trial power in mixed-efects models and compared the performance of the NfL model with two currently used predictive approaches,which anticipate disease progression using the ALSFRS-R decrease during a three-month observational period(lead-in)or since disease onset(ΔFRS).Results:Among the parameters provided,the NfL levels(P<0.001)and the interaction with site of onset(P<0.01)contributed signifcantly to the prediction,forming a robust NfL prediction model(R=0.67).Model application in the trial cohorts confrmed its applicability and revealed superiority over lead-in andΔFRS-based approaches.The NfL model improved statistical power by 61%and 22%(95%confdence intervals:54%-66%,7%-29%).Conclusion:The use of the NfL-based prediction model to compensate for clinical heterogeneity in ALS could signif‑cantly increase the trial power.NCT00868166,registered March23,2009;NCT02306590,registered December 2,2014. | Simon Witzel Felix Frauhammer† Petra Steinacker David Devos Pierre‑François Pradat Vincent Meininger Stefen Halbgebauer Patrick Oeckl Joachim Schuster Simon Anders Johannes Dorst Markus Otto Albert C.Ludolph | 2021 | Translational Neurodegeneration2021，10，3： | 1 |
| 19 | Recent advances in recognition elements of food and environmental biosensors: A review显示文摘 | DORST B V MEHTA J BEKAERTB K | 2010 | Biosensors and Bioelectronics2010，26，4： | 1 |
| 20 | Phage display as a method for discovering cellular targets of small molecules显示文摘 | Dorst B V Mehta J Rouah-Martin E | 2012 | Methods2012，58，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员